You are here

upadacatinib

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

Motley Fool

Vertex Pharmaceuticals

tezacaftor/ivacaftor

trastuzumab deruxtecan

Flag link:

2 Things Investors Are Missing About AbbVie

2 Things Investors Are Missing About AbbVie

Motley Fool

Flag link:

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

Pharmaforum

priority review

rheumatoid arthritis

Flag link:

5 Experimental New Drugs That Could Be Worth $47 Billion

5 Experimental New Drugs That Could Be Worth $47 Billion

Motley Fool

VX-659 + tezacaftor + ivacaftor

Vertex Pharmaceuticals

Flag link: